CA2624110C - Formulation en cachet a administrer oralement et a dissolution rapide - Google Patents

Formulation en cachet a administrer oralement et a dissolution rapide Download PDF

Info

Publication number
CA2624110C
CA2624110C CA2624110A CA2624110A CA2624110C CA 2624110 C CA2624110 C CA 2624110C CA 2624110 A CA2624110 A CA 2624110A CA 2624110 A CA2624110 A CA 2624110A CA 2624110 C CA2624110 C CA 2624110C
Authority
CA
Canada
Prior art keywords
wafer
agent
gel
heating
pharmaceutical agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2624110A
Other languages
English (en)
Other versions
CA2624110A1 (fr
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ctt Pharma Inc
Original Assignee
Pankaj Modi
Fenwafe Inc.
Ctt Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pankaj Modi, Fenwafe Inc., Ctt Pharma Inc. filed Critical Pankaj Modi
Priority to CA2624110A priority Critical patent/CA2624110C/fr
Publication of CA2624110A1 publication Critical patent/CA2624110A1/fr
Application granted granted Critical
Publication of CA2624110C publication Critical patent/CA2624110C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un cachet administrable par voie orale qui se compose d'au moins un agent constituant une pellicule physiologiquement acceptable. Le cachet est formé en mélangeant l'agent constituant une pellicule à une solution aqueuse pour former un gel et en exposant le gel à plusieurs cycles de réchauffement et de refroidissement. Le cachet se dissout rapidement et convient à l'administration d'agents pharmaceutiques.
CA2624110A 2008-03-27 2008-03-27 Formulation en cachet a administrer oralement et a dissolution rapide Active CA2624110C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2624110A CA2624110C (fr) 2008-03-27 2008-03-27 Formulation en cachet a administrer oralement et a dissolution rapide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2624110A CA2624110C (fr) 2008-03-27 2008-03-27 Formulation en cachet a administrer oralement et a dissolution rapide

Publications (2)

Publication Number Publication Date
CA2624110A1 CA2624110A1 (fr) 2008-11-14
CA2624110C true CA2624110C (fr) 2010-11-09

Family

ID=39971178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2624110A Active CA2624110C (fr) 2008-03-27 2008-03-27 Formulation en cachet a administrer oralement et a dissolution rapide

Country Status (1)

Country Link
CA (1) CA2624110C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Also Published As

Publication number Publication date
CA2624110A1 (fr) 2008-11-14

Similar Documents

Publication Publication Date Title
US8623401B2 (en) Wafer formulation
ES2260961T3 (es) Peliculas consumibles por via bucal de disolucion rapida.
US9492379B2 (en) Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent
US20120121724A1 (en) Film comprising therapeutic agents
US20030211136A1 (en) Fast dissolving orally consumable films containing a sweetener
US20120148689A1 (en) Film comprising active drugs
US20100215774A1 (en) Film comprising nitroglycerin
WO2006063189A2 (fr) Systeme d'administration de medicament a desintegration rapide
CA2520986C (fr) Film physiologiquement compatible
CA2624110C (fr) Formulation en cachet a administrer oralement et a dissolution rapide
CA2572461C (fr) Film physiologiquement compatible
MXPA01001539A (en) Fast dissolving orally consumable films

Legal Events

Date Code Title Description
EEER Examination request